Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Atrium Therapeutics, Inc. (RNA) Stock · SELL · CRISIS | LOPJLB

Atrium Therapeutics, Inc. (RNA)

Healthcare · Biotechnology · NASDAQ · US

$8.26+4.16%Close

SELLCRISIS · day 23

RNA▼ SELL

$8.26+4.16%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-15

Market cap: $141M
Beta: 0.37
P/E (TTM): -2.08

Short % float: 21.61%
Days to cover: 8.2
SI change: +1.4%

1W: +1.47%
1M: -21.41%

vs SPY 1W: -0.08%
vs SPY 1M: -23.17%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a…

Employees: 511
Headquarters: US
Founded: 2026
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 17.1M
Float: 91.9%

atriumtherapeutics.com ↗

Key executives

Husam Younis — Chief Scientific Officer

Brendan Winslow — Chief Financial Officer

Steven George Hughes — Chief Medical Officer

SEC filings

EDGAR · CIK 20931010 · RNA

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish850.0%

Neutral850.0%

Bearish00.0%

L $25.00Avg $25.00H $25.00

Target$25.00+202.66%

Last$8.26

Company news

prnewswire.com · 2d ago

Atrium Therapeutics Announces $50 Million Private Placement

defenseworld.net · 3d ago

Avidity Biosciences (NASDAQ:RNA) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

prnewswire.com · 18d ago

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

defenseworld.net · 30d ago

Avidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?

prnewswire.com · 38d ago

Atrium Therapeutics to Participate in Upcoming Investor Conferences

prnewswire.com · 50d ago

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

prnewswire.com · 57d ago

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

prnewswire.com · 58d ago

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

247wallst.com · 65d ago

Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More

defenseworld.net · 80d ago

Avidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average – Here’s Why

prnewswire.com · 81d ago

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

prnewswire.com · 88d ago

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Market news & ticker search · RSS for RNA

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE